Marshall Wace’s Cytek Biosciences CTKB Stock Holding History

Marshall Wace’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Buy	+441,704	New	+$1.89M	﹤0.01%	1869
2025 Q4	–	Sell	-134,286	Closed	-$466K	–	3045
2025 Q3	$466K	Sell	134,286 -127,066	-49%	-$477K	﹤0.01%	2258
2025 Q2	$889K	Buy	+261,352	New	+$871K	﹤0.01%	1905
2024 Q2	–	Sell	-68,591	Closed	-$460K	–	2615
2024 Q1	$460K	Buy	+68,591	New	+$543K	﹤0.01%	1959
2022 Q3	–	Sell	-54,096	Closed	-$582K	–	3407
2022 Q2	$582K	Buy	+54,096	New	+$538K	﹤0.01%	2723
2022 Q1	–	Sell	-7,160	Closed	-$117K	–	3454
2021 Q4	$117K	Buy	+7,160	New	+$150K	﹤0.01%	3343

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's CTKB Position: Q2 2026 in Review

Marshall Wace opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 441,704 shares worth $1.96M. The stake represents ﹤0.01% of the portfolio and ranks #1869 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CTKB as recently as Q3 2025.

Marshall Wace first reported a position in CTKB in Q4 2021 and has held it in 6 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Marshall Wace held 441,704 shares of Cytek Biosciences worth $1.96M as of Q2 2026.
Cytek Biosciences was a new Marshall Wace position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1869 holding.
Marshall Wace first reported a position in Cytek Biosciences in Q4 2021 and has held it in 6 quarters since.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.